Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF16.46B
• Dividend Yield: 0.92%
• Average Volume (3M): 259.47K
• Price to Earnings (P/E): 42.6
• Beta (1Y): 1.41
• Revenue Growth: 3.82%
• EPS Growth: 57.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 269,700
• 30 Day Avg. Volume: 259,471
• PEG Ratio: 6.85
• Price to Book (P/B): 9.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 56.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF128.29
• Price Target Upside: 22.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 77 Outperform
• Price Target: CHF119.00 ▲(13.88%Upside)

Straumann Holding AG's strong financial performance and positive earnings call sentiment drive its robust overall score. While technical indicators are neutral and valuation is high, the company's strategic initiatives and regional growth provide a promising outlook despite some macroeconomic challenges.

Positive Factors

Earnings

The company reported a strong start with top-line results beating expectations, indicating robust growth.

Market Performance

Asia Pacific achieved a historical high in revenue with significant growth, driven by strong market performance.

Negative Factors

Geographic Challenges

There is concern over sequentially slower North American growth and a lack of clarity on aligner products.

Macroeconomic Conditions

Macro and consumer picture in the US has worsened, potentially affecting Straumann's performance.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Straumann Holding AG generates revenue primarily through the sale of its comprehensive range of dental products and solutions. Key revenue streams include dental implants, which are a significant portion of their portfolio, and restorative products that support the reconstruction of dental functions. The company also earns from its digital dentistry solutions, which include CAD/CAM systems and intraoral scanners. Additionally, Straumann benefits from the sale of biomaterials used in oral tissue regeneration and orthodontic products designed for dental alignment. Strategic partnerships with dental clinics, research institutions, and distribution networks further enhance its market presence and contribute to its revenue. The company's focus on innovation and expanding its digital solutions portfolio are critical factors in driving its earnings growth.

Straumann Holding AG Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.47B	2.50B	2.41B	2.32B	2.02B	1.43B
Gross Profit	1.78B	1.78B	1.79B	1.70B	1.53B	1.03B
EBITDA	660.78M	726.15M	685.07M	685.37M	591.48M	230.45M
Net Income	270.67M	388.32M	246.07M	434.79M	396.08M	91.28M
Balance Sheet
Total Assets	2.46B	3.62B	3.40B	3.45B	3.05B	2.62B
Cash, Cash Equivalents and Short-Term Investments	261.79M	383.07M	413.54M	697.11M	881.50M	632.49M
Total Debt	455.50M	413.89M	412.35M	705.20M	711.66M	731.66M
Total Liabilities	1.09B	1.58B	1.56B	1.60B	1.55B	1.41B
Stockholders Equity	1.36B	2.04B	1.84B	1.85B	1.50B	1.20B
Cash Flow
Free Cash Flow	341.88M	315.62M	316.61M	220.94M	440.97M	295.34M
Operating Cash Flow	505.22M	483.39M	503.95M	416.38M	561.94M	377.41M
Investing Cash Flow	-343.62M	-352.62M	-349.33M	-449.84M	-185.20M	-145.64M
Financing Cash Flow	-424.99M	-169.06M	-424.40M	-140.35M	-122.90M	153.33M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 104.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Negative. The current price of 104.5 is below the 20-day moving average (MA) of 105.68, below the 50-day MA of 104.77, and below the 200-day MA of 115.35, indicating a bearish trend. The MACD of -0.94 indicates Positive momentum. The RSI at 43.09 is Neutral, neither overbought nor oversold. The STOCH value of 28.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STMN	77 Outperform	CHF16.46B	42.57		0.92%	3.82%	57.08%
SOON	74 Outperform	CHF13.85B	26.54		1.83%	6.58%	-10.02%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
ALC		$43.94B	38.68	5.23%	0.38%	―	―
TCHBF		$2.58B	33.54	4.84%	1.82%	―	―
0QLQ		CHF5.73B	65.58	13.49%	0.46%	―	―
GALD		CHF26.89B	132.17		0.13%	―	―

Straumann Holding AG Corporate Events

Straumann Announces Major Investment in Villeret Amid Strategic Shift to China

Straumann Holding AG has announced a strategic investment of 60 to 80 million CHF in its Villeret site over the next five years to enhance its role as a competence center for innovation and precision manufacturing. This investment will focus on advanced technologies and infrastructure modernization, while also addressing workforce adjustments due to the relocation of production for the Chinese market to a new campus in Shanghai. The move aims to secure competitiveness in China, which accounts for over 15% of Straumann’s global revenue, and ensure long-term growth and market positioning. The changes could affect up to 250 positions in Villeret, with a consultation process underway to explore socially acceptable solutions.

The most recent analyst rating on (CH:STMN) stock is a Buy with a CHF157.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Holding AG Reports Strong Q1 2025 Growth Amid Global Challenges

Straumann Holding AG reported a strong start to 2025 with a 11.0% organic sales growth in the first quarter, reaching CHF 680.7 million. The EMEA and APAC regions were notable for their contributions, with significant growth in China and the introduction of new products like the iEXCEL implant system. Despite macroeconomic uncertainties, Straumann’s diversified portfolio and strategic partnerships have positioned it well for continued success, as evidenced by positive responses at the International Dental Show and sustained growth in digital solutions and orthodontics.

Straumann Shareholders Approve All Board Proposals at General Meeting

At the recent General Meeting, Straumann Holding AG’s shareholders approved all proposals from the Board of Directors, including financial statements, compensation reports, and capital appropriations for the fiscal year 2024. Key decisions included a dividend payout and the re-election of board members and auditors, reflecting strong shareholder support and stable governance. These approvals are expected to reinforce Straumann’s market position and operational stability, benefiting stakeholders by ensuring continued strategic alignment and financial health.